Follicular thyroid carcinoma is a malignant epithelial neoplasm derived from thyroid follicular cells, characterized by a predominantly follicular architecture and by a histological diagnosis based on the demonstration of capsular invasion and/or vascular invasion. Unlike papillary carcinoma, it is not defined by the typical nuclear alterations of papillary carcinoma and, in most cases, does not initially spread through the cervical lymphatic system. Its clinical identity arises precisely from this contrast: follicular carcinoma may appear cytologically similar to a follicular adenoma, but it becomes a carcinoma when it extends beyond the tumor capsule or invades blood vessels, thereby acquiring the potential for hematogenous spread to the lungs and bones.
It is the second most common differentiated thyroid carcinoma after papillary carcinoma, with an incidence that varies according to age, sex, iodine intake, histological diagnostic criteria, and geographical distribution. It is more frequent in adults and older individuals than classic papillary carcinoma, shows a female predominance, and tends to be relatively more common in areas with iodine deficiency or a long-standing history of nodular goiter. Prognosis is highly heterogeneous: minimally invasive forms confined to the capsule often have an excellent course, whereas extensively angioinvasive, widely invasive, or metastatic forms require more aggressive treatment and prolonged follow-up. The central clinical issue is distinguishing an indeterminate follicular lesion from true carcinoma and, once malignancy has been confirmed, defining the significance of vascular invasion, local extension, and distant metastases.
Follicular carcinoma arises from the thyroid follicular epithelium, the same cellular compartment that produces thyroglobulin, takes up iodine, and participates in the synthesis of thyroxine (T4) and triiodothyronine (T3). This origin places it among differentiated thyroid carcinomas, but its definition does not overlap with that of papillary carcinoma. In follicular carcinoma, the cells form follicles, microfollicles, trabeculae, or solid structures with variable amounts of colloid, without the diagnostic nuclear features of papillary carcinoma. The discriminating element is not cytological atypia alone, but the demonstration that the tumor has crossed its own capsule or invaded capsular or extracapsular venous vessels. The diagnosis is therefore based on histological invasiveness, rather than being a purely cytological diagnosis.
This feature explains why thyroid fine-needle aspiration, although essential in the initial diagnostic pathway, cannot reliably distinguish follicular adenoma from follicular carcinoma. Both may show follicular cellularity, microfollicles, scant colloid, and cellular monotony; what the cytological specimen lacks is the ability to assess the capsule and vessels continuously. Cytology may indicate a “follicular neoplasm” or “suspicious for a follicular neoplasm,” but the term carcinoma requires examination of the surgically removed nodule, with careful sampling of the capsule. This limitation is a decisive aspect of thyroid diagnostics, because it prevents every indeterminate follicular nodule from being treated as a confirmed carcinoma.
Contemporary classification distinguishes minimally invasive, encapsulated angioinvasive, and widely invasive forms. In minimally invasive follicular carcinoma, infiltration is limited and may consist of capsular invasion with absent or minimal vascular invasion. In encapsulated angioinvasive follicular carcinoma, the tumor retains an expansile profile and a recognizable capsule but invades blood vessels; the risk increases with the number of foci of vascular invasion. In widely invasive follicular carcinoma, the tumor diffusely infiltrates the thyroid parenchyma and surrounding tissues, with loss of a clearly defined capsular boundary. Separation of these categories is clinically relevant because prognosis depends much more on extensive angioinvasion and widespread infiltration than on the mere presence of minimal capsular penetration.
Follicular carcinoma must not be confused with the follicular variant of papillary thyroid carcinoma. The follicular variant of papillary carcinoma has a follicular architecture but nuclei typical of papillary carcinoma; true follicular carcinoma, by contrast, does not possess those nuclear alterations as its dominant diagnostic criterion. This distinction is essential because the two neoplasms have molecular patterns, routes of spread, and clinical management that are not interchangeable. Similarly, noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) must not be included among invasive follicular carcinomas, because it shows no capsular or vascular invasion and has an extremely indolent biological behavior. Correct diagnostic boundaries protect against overdiagnosis and overtreatment.
Oncocytic carcinoma, historically called Hürthle cell carcinoma, must be considered separately. It may share with follicular carcinoma the need to demonstrate capsular or vascular invasion, but it is now regarded as a distinct category because of its oncocytic cytology, mitochondrial biology, molecular profile, and clinical behavior. A follicular neoplasm containing focal oncocytic cells does not automatically become an oncocytic carcinoma; likewise, an oncocytic carcinoma must not be equated with conventional follicular carcinoma merely because it invades the capsule or vessels. Correct classification requires assessment of the predominant cellular component, the pattern of invasion, and the overall profile of the follicular neoplasm.
The pathologist must report tumor size, capsular status, number and location of foci of vascular invasion, extent of capsular invasion, margins, any extrathyroidal extension, necrosis, mitotic activity, widely invasive growth pattern, lymph node involvement if sampled, and the presence of metastases. Vascular invasion must be distinguished from retraction or displacement artifacts, because overinterpretation may transform a low-risk tumor into apparently more aggressive disease. The quality of surgical specimen sampling is therefore an integral part of the diagnosis, rather than a technical detail. In follicular carcinoma, the histological report directly guides completion surgery, the indication for radioactive iodine, and the intensity of follow-up.
In most patients, follicular carcinoma has no single demonstrable cause. Carcinogenesis results from the accumulation of genetic and microenvironmental alterations that transform a follicular proliferation into an autonomous neoplasm capable of invading the capsule and vessels. The most relevant epidemiological factors are advanced adult age, female sex, residence in areas with low iodine intake, long-standing nodular goiter, and a history of follicular nodules. Exposure to ionizing radiation increases the overall risk of differentiated thyroid tumors, but the classic association is stronger for papillary carcinoma than for follicular carcinoma. In follicular carcinoma, the most typical context is a clonal follicular proliferation that acquires invasive capacity.
Iodine deficiency modifies thyroid physiology because it reduces the availability of the substrate required for hormone synthesis, increases stimulation by thyroid-stimulating hormone (TSH), and promotes goiter, nodularity, and follicular hyperplasia. Tissue exposed for years to proliferative stimulation and nodular remodeling provides more opportunities for clonal selection, functional autonomy, and accumulation of genetic alterations. This does not mean that every goiter becomes a carcinoma or that iodine deficiency is a sufficient direct cause; it indicates a biological environment in which follicular neoplasms are relatively more frequent. The relationship between thyrotropic stimulation, nodular growth, and transformation must be understood as an increase in probability, rather than as an obligatory sequence.
At the molecular level, follicular carcinoma often belongs to the group of “RAS-like” tumors. Mutations involving neuroblastoma RAS viral oncogene homolog (NRAS), Harvey rat sarcoma viral oncogene homolog (HRAS), or Kirsten rat sarcoma viral oncogene homolog (KRAS) activate proliferative and survival signaling pathways involving mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT). Unlike classic papillary carcinoma, which is frequently dominated by BRAF-like events, follicular carcinoma often preserves follicular architecture, thyroid differentiation, and an initially expansile growth pattern. A RAS mutation does not by itself establish definite malignancy, because it may also be present in adenomas and borderline lesions, but it indicates a molecular program consistent with follicular neoplasia.
Another representative alteration is the paired box gene 8/peroxisome proliferator-activated receptor gamma fusion (PAX8::PPARG). PAX8 is a transcription factor essential for thyroid differentiation, whereas PPARG regulates adipogenic, metabolic, and differentiation programs; the fusion disrupts transcriptional control and promotes follicular neoplastic growth. Alterations in the PI3K/AKT pathway, including changes in phosphatase and tensin homolog (PTEN), may contribute to progression, particularly when associated with additional events. Follicular carcinogenesis is therefore less centered on a single universal driver and more on a network of signals that support clonal expansion, cell survival, and invasiveness.
Mutations in the promoter of telomerase reverse transcriptase (TERT) have particular prognostic significance when they occur in invasive or metastatic follicular tumors. Telomerase activation enables telomere maintenance, prolonged replicative capacity, and selection of more aggressive clones. Alterations involving eukaryotic translation initiation factor 1A X-linked (EIF1AX), DICER1 ribonuclease III (DICER1), isocitrate dehydrogenase (IDH), tumor protein p53 (TP53), or other genes may also occur in specific subgroups or during progression toward poorly differentiated forms. The presence of TERT, particularly when associated with other progression events, should prompt consideration of a higher biological risk than that of a minimally invasive carcinoma without adverse markers.
The transition from follicular adenoma to follicular carcinoma cannot always be demonstrated as a linear sequence in every patient, but the most plausible biological model proposes that some initially encapsulated follicular neoplasms acquire the ability to cross the capsule and penetrate vessels. Capsular invasion indicates breach of the local anatomical barrier; vascular invasion indicates direct access to the venous circulation and explains the predilection for hematogenous metastases. Angioinvasion is therefore the pathophysiological bridge between histology and clinical behavior: once the tumor enters blood vessels, the risk of systemic dissemination becomes biologically concrete.
Dedifferentiation is less common but clinically important. Some follicular carcinomas accumulate alterations that reduce the expression of thyroglobulin, thyroid peroxidase (TPO), sodium iodide symporter (NIS), and other thyroid-specific genes, progressively losing their ability to take up iodine. This phenomenon reduces the effectiveness of radioactive iodine and may be associated with more rapid growth, necrosis, increased mitotic activity, and transformation into poorly differentiated or anaplastic carcinoma. Loss of thyroid differentiation is not merely a morphological change, but a functional transformation that alters prognosis and therapeutic options.
Follicular carcinoma often grows as a solitary, encapsulated, or apparently well-circumscribed nodule, sometimes indistinguishable from a follicular adenoma on ultrasound and cytology. This orderly appearance may be misleading because malignant behavior does not necessarily arise from irregular ultrasound margins or microcalcifications, but from the histological ability to cross the capsule or enter blood vessels. A rounded, solid, isoechoic, or mildly hypoechoic nodule may therefore conceal a follicular carcinoma. Clinical assessment must recognize the limitations of morphological indicators when the main biological issue is capsular and vascular invasion.
The most characteristic route of spread is hematogenous. Invasion of capsular or peritumoral venous vessels allows neoplastic cells to reach the systemic circulation, lungs, and skeleton. This differentiates follicular carcinoma from papillary carcinoma, in which cervical lymph node metastases are much more frequent. Lymph nodes may be involved in follicular carcinoma, but nodal involvement is less typical and, when present, should prompt careful reassessment of the histological type, a poorly differentiated component, the follicular variant of papillary carcinoma, or another diagnosis. The distinctive feature remains hematogenous dissemination.
Pulmonary metastases may present as single or multiple nodules, diffuse micronodular disease, or progressive non-iodine-avid lesions. When they retain differentiation and functional NIS expression, they may respond to radioactive iodine; when iodine uptake is lost, radiological surveillance, local therapies, or systemic treatment may be required according to growth and symptoms. Bone metastases are often osteolytic and may involve the vertebrae, pelvis, ribs, femur, skull, and other skeletal sites, causing pain, pathological fractures, spinal cord compression, or neurological deficits. Bone involvement has a major impact because local control of a bone metastasis may require radiotherapy, surgery, orthopedic stabilization, embolization, or ablation.
Local extrathyroidal invasion is less frequent in minimally invasive forms but may occur in widely invasive tumors. The tumor may infiltrate perithyroidal soft tissues, muscles, trachea, esophagus, recurrent laryngeal nerve, or vascular structures, causing dysphonia, dysphagia, cough, hemoptysis, dyspnea, or fixation of the cervical mass. Macroscopic invasion changes both staging and surgical strategy because it requires more complex resections and multidisciplinary assessment. Extrathyroidal invasion must be documented precisely, distinguishing surgical adherence, minimal microscopic extension, and true macroscopic infiltration.
Follicular carcinoma may grow slowly for years, particularly in encapsulated forms with minimal invasion, or may progress rapidly when angioinvasion is extensive, distant metastases are present, or the tumor loses differentiation. This variability explains why nodule diameter alone is insufficient: a small but angioinvasive tumor may metastasize, whereas a large tumor with limited capsular invasion alone may have a favorable course. The invasive biology of follicular carcinoma therefore requires an assessment integrating size, histology, vascular involvement, margins, metastases, and response to iodine.
The most common presentation is a solitary thyroid nodule or a dominant nodule within a multinodular goiter, often detected by palpation, ultrasound, or neck imaging performed for other reasons. The patient is usually euthyroid because follicular carcinoma rarely produces enough hormone to cause clinical thyrotoxicosis; however, it may coexist with autonomous nodules, multinodular goiter, or functional abnormalities independent of the tumor. The medical history should reconstruct the duration of the nodule, progressive growth, history of goiter, iodine deficiency, cervical irradiation, family history, dysphonia, dysphagia, dyspnea, bone pain, fractures, persistent cough, and weight loss. The presence of skeletal pain in a patient with an indeterminate follicular nodule should raise suspicion of metastatic disease, even when the neck is minimally symptomatic.
On physical examination, the thyroid may contain a nodule that moves with swallowing, has increased consistency, and is often painless. Fixation to deep planes, rapid growth, dysphonia, tracheal deviation, or the onset of compressive symptoms indicate possible local invasion or another aggressive disease and require prompt investigation. Cervical lymph nodes must still be palpated, but in follicular carcinoma their absence is not as reassuring as in papillary carcinoma because systemic dissemination may occur through the venous circulation without evident lymphadenopathy. Physical examination must therefore combine cervical assessment with a search for signs of distant metastases.
Metastatic manifestations may precede the diagnosis of the thyroid tumor. An osteolytic vertebral lesion, pathological fracture, skull swelling, pelvic pain, spinal cord compression, or pulmonary nodules may be the first indication of an occult follicular carcinoma. In these cases, the diagnosis may emerge from biopsy of the metastatic lesion, immunohistochemical positivity for thyroglobulin, thyroid transcription factor 1 (TTF-1), or paired box gene 8 (PAX8), and subsequent identification of the thyroid tumor. Presentation with an initial metastasis is less common than diagnosis following detection of a thyroid nodule, but it is clinically characteristic of the hematogenous profile of the disease.
In older individuals, follicular carcinoma may be more likely to present as a widely invasive form, with distant metastases or comorbidities that complicate surgery and radioactive iodine therapy. In younger patients, minimally invasive forms often have an excellent prognosis, but the presence of extensive vascular invasion or metastases completely changes the clinical picture. Female sex increases diagnostic frequency but does not replace anatomical and histological prognostic factors. Clinical assessment must avoid shortcuts: age, sex, and size help define risk, but angioinvasion remains one of the principal determinants of behavior.
Symptoms of hyperthyroidism or hypothyroidism are not typical of the neoplasm itself and must be interpreted separately. A suppressed thyroid-stimulating hormone (TSH) level suggests functional autonomy of one or more nodules and requires scintigraphy because a hyperfunctioning nodule has a lower probability of malignancy than a nonfunctioning nodule; this does not exclude all risk, but it changes the diagnostic sequence. An elevated TSH level may reflect concomitant chronic thyroiditis or thyroid insufficiency. Thyroid function defines the endocrine context, whereas the oncological diagnosis of a follicular neoplasm remains linked to morphology and invasion.
The diagnostic pathway begins with medical history, physical examination, measurement of TSH, and thyroid and cervical ultrasound. Ultrasound assesses size, composition, echogenicity, margins, peripheral halo, vascularity, possible extrathyroidal extension, and lymph nodes. In follicular nodules, the ultrasound profile may be less specific than in papillary carcinoma: microcalcifications, irregular margins, and a taller-than-wide shape may occur, but many follicular carcinomas are solid, well-circumscribed, isoechoic, or mildly hypoechoic nodules. Ultrasound is primarily used to determine whether fine-needle aspiration should be performed, map the thyroid gland, and identify any signs of extrathyroidal disease.
If TSH is suppressed, thyroid scintigraphy often precedes fine-needle aspiration of the dominant nodule because it identifies hyperfunctioning, isofunctioning, or hypofunctioning nodules. Most follicular carcinomas are nonfunctioning, but coexistence with nodular autonomy is possible, particularly in multinodular goiters. If TSH is normal or elevated, ultrasound-guided fine-needle aspiration is indicated according to nodule size and ultrasound risk. According to The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), the cytological result may fall into the categories of atypia of undetermined significance, follicular neoplasm/suspicious for a follicular neoplasm, suspicious for malignancy, or, more rarely, malignancy. The essential point is that the category follicular neoplasm is not equivalent to a definite follicular carcinoma.
Fine-needle aspiration describes the cells but cannot reliably assess the entire capsule and vessels. For this reason, a definite preoperative diagnosis of follicular carcinoma is generally impossible when the tumor does not already have documented metastases or evident macroscopic invasion. Core needle biopsy may provide more tissue architecture than cytology in selected cases, but it does not systematically resolve the issue of capsular and vascular invasion. Intraoperative frozen-section examination also has limited usefulness in follicular nodules because invasion may be focal and require extensive sampling. Definitive diagnosis requires histological examination of the removed nodule.
According to the World Health Organization (WHO) classification and the approach adopted by international guidelines, diagnosis of follicular carcinoma requires demonstration of an invasive follicular thyroid neoplasm lacking the diagnostic nuclear features of papillary carcinoma. The logical sequence leading to diagnosis must distinguish preoperative suspicion, histological confirmation, and postoperative prognostic stratification:
Diagnosis of follicular carcinoma
The differential diagnosis includes follicular adenoma, hyperplastic nodule in multinodular goiter, follicular tumor of uncertain malignant potential, NIFTP, follicular variant of papillary carcinoma, oncocytic carcinoma, poorly differentiated carcinoma, medullary carcinoma with a rare follicular pattern, intrathyroidal metastases, and parathyroid lesions. Immunohistochemistry may assist in complex cases: thyroglobulin, TTF-1, and PAX8 support a thyroid follicular origin, whereas calcitonin supports medullary carcinoma and parathyroid hormone supports parathyroid tissue. However, no immunohistochemical marker replaces the demonstration of invasion when the diagnostic problem is distinguishing follicular adenoma from follicular carcinoma.
Molecular testing may be useful in cytologically indeterminate nodules, but it must not be interpreted as absolute proof of follicular carcinoma. RAS mutations, PAX8::PPARG fusion, and alterations involving DICER1, EIF1AX, or other genes may increase or modify the probability of neoplasia, but they do not independently demonstrate capsular or vascular invasion. In already diagnosed tumors, particularly metastatic or radioactive iodine-refractory forms, molecular profiling becomes more important because it identifies prognostic alterations or therapeutic targets. The value of molecular testing therefore depends on the clinical question: estimating preoperative risk or guiding advanced treatment of progressive disease.
Second-level investigations are selected according to anatomical risk. Computed tomography (CT) or magnetic resonance imaging (MRI) of the neck and mediastinum is indicated when extrathyroidal invasion, a retrosternal mass, or tracheal, esophageal, or vascular involvement is suspected. Chest CT evaluates pulmonary metastases when the risk is high or thyroglobulin is elevated. Bone imaging, targeted MRI, or fluorodeoxyglucose positron emission tomography (FDG-PET) is reserved for bone pain, elevated thyroglobulin with a negative iodine scan, advanced disease, or suspected dedifferentiation. Investigations should search for clinically relevant extension, rather than generating a cascade of incidental findings.
In follicular thyroid carcinoma, anatomical staging, mortality risk, and the risk of persistence or recurrence must be distinguished. The eighth edition of the American Joint Committee on Cancer (AJCC) staging system uses the tumor-node-metastasis (TNM) classification and is primarily intended to estimate disease-specific survival. The American Thyroid Association (ATA) stratification system instead weighs factors such as angioinvasion, macroscopic invasion, completeness of resection, distant metastases, and response to therapy. This distinction is particularly important in follicular carcinoma because an apparently localized tumor may carry a different risk according to the extent of vascular invasion.
The T category describes the size and local extension of the primary tumor. In follicular carcinoma, size is relevant but does not replace histological assessment of capsular and vascular invasion. Anatomical classification must be reported explicitly because it guides prognosis, the indication for completion surgery, the use of radioactive iodine, and follow-up. The T category is defined as follows:
T category in follicular thyroid carcinoma
The N category describes regional lymph node involvement. Lymph node metastases are less frequent in follicular carcinoma than in papillary carcinoma, but they must still be sought and documented when present. Metastatic lymph nodes may indicate more advanced disease, an unfavorable biological component, or the need to reconsider the differential diagnosis with the follicular variant of papillary carcinoma. The N category is defined as follows:
N category in follicular thyroid carcinoma
The M category is decisive in follicular carcinoma because hematogenous dissemination to the lungs and bones is one of its most characteristic clinical features. The presence of distant metastases changes the stage, prognosis, and therapeutic approach, particularly when the lesions do not take up radioactive iodine or progress over time. The M category must always be stated explicitly:
M category in follicular thyroid carcinoma
After T, N, and M have been defined, the AJCC stage is assigned according to the patient’s age, using 55 years as the threshold. In patients younger than 55 years, the system distinguishes only between the absence and presence of distant metastases because disease-specific mortality generally remains low when M0. This does not mean that vascular invasion, tumor size, or surgery are irrelevant; it means that, for AJCC staging, the main prognostic determinant in this age group is M1:
AJCC staging for patients younger than 55 years
In patients aged 55 years or older, AJCC staging becomes more complex because size, gross invasion, lymph nodes, and distant metastases have a greater impact on disease-specific survival. The classification must be reported without ambiguity because a tumor confined to the thyroid, disease with regional lymph node involvement, and disease with bone metastases do not carry the same clinical significance. In patients aged at least 55 years, AJCC staging is as follows:
AJCC staging for patients aged at least 55 years
ATA recurrence risk stratification adds information that AJCC staging does not adequately describe. In follicular carcinoma, the most important detail is the extent of vascular invasion because access to blood vessels is the anatomical prerequisite for hematogenous metastasis. A minimally invasive form with capsular invasion alone carries a very different risk from an encapsulated carcinoma with extensive angioinvasion or a widely invasive form. ATA stratification must therefore be applied after complete histological diagnosis:
ATA risk in follicular thyroid carcinoma
Initial stratification is subsequently modified according to response to therapy. After surgery, possible radioactive iodine therapy, and monitoring with thyroglobulin, anti-thyroglobulin antibodies, and imaging, the patient may be reclassified as having an excellent response, an indeterminate response, a biochemical incomplete response, or a structural incomplete response. This reassessment is particularly important in follicular carcinoma because pulmonary or bone metastases may emerge after a prolonged interval, whereas many minimally invasive forms remain cured after adequate surgery. Dynamic risk stratification prevents both undertreatment of angioinvasive forms and excessive therapy in very-low-risk disease.
Treatment of follicular carcinoma often begins with surgery performed for an indeterminate follicular nodule. In many patients, diagnostic and therapeutic lobectomy is the first step because it allows removal of the nodule, assessment of the capsule and vessels, and determination of whether the lesion is an adenoma, a borderline lesion, or a carcinoma. If histology demonstrates a completely resected, minimally invasive carcinoma without significant angioinvasion or other adverse factors, lobectomy may be sufficient. If extensive angioinvasion, a large tumor, positive margins, extrathyroidal extension, bilateral disease, metastases, or the need for more sensitive thyroglobulin-based follow-up emerges, completion thyroidectomy is considered. The surgical approach must follow the histological risk.
Total thyroidectomy is indicated or strongly considered in widely invasive forms, tumors with extensive vascular invasion, large neoplasms carrying intermediate or high risk, locally advanced disease, distant metastases, and cases in which radioactive iodine treatment is planned. The rationale is to remove all thyroid tissue, facilitate radioiodine therapy, improve interpretation of thyroglobulin, and reduce the risk of residual neoplastic tissue. However, the extent of surgery must be balanced against the risks of hypoparathyroidism, recurrent laryngeal nerve injury, and permanent replacement therapy. Total thyroidectomy should not be automatic for every minimally invasive microcarcinoma but becomes appropriate when required by the biological profile.
Prophylactic lymph node dissection does not have the same role as it may have in some forms of papillary carcinoma because follicular carcinoma spreads more frequently through the bloodstream and less frequently to cervical lymph nodes. Clinically or ultrasonographically suspicious lymph nodes must, however, be assessed and, if metastatic, treated with therapeutic dissection of the involved compartment. Central or lateral dissection without evidence of lymph node disease is not justified in low-risk follicular carcinomas because it increases morbidity without a clear benefit. Lymph node surgery must remain therapeutic and guided by clinical, ultrasound, cytological, or intraoperative evidence.
Radioactive iodine with iodine-131 is used selectively. It has a strong indication in iodine-avid metastases, high-risk forms, widely invasive tumors, extensive angioinvasion, and cases in which remnant ablation improves staging, treatment, or follow-up. It may be avoided in minimally invasive, intrathyroidal, completely resected carcinomas without adverse factors. Follicular carcinoma often retains differentiation and the ability to take up iodine, but this is not guaranteed, particularly in dedifferentiated or progressive metastatic forms. The benefit of radioactive iodine depends on the presence of iodine-avid tumor tissue and the balance between oncological risk and toxicity.
Levothyroxine therapy is required after total thyroidectomy and may be necessary after lobectomy if residual thyroid function is insufficient. In patients with intermediate- or high-risk disease, levothyroxine is also used to reduce TSH because TSH may stimulate the growth and survival of residual differentiated thyroid cells. Suppression must be proportionate: more intense in persistent or high-risk disease, moderate in intermediate-risk disease, and less aggressive in low-risk patients with an excellent response. Excessive suppression may cause atrial fibrillation, bone loss, tachycardia, and cardiovascular deterioration. The TSH target must be individualized according to risk, age, cardiovascular status, bone health, and response to therapy.
Metastatic disease requires integration of systemic therapy and local treatments. Iodine-avid pulmonary metastases may respond to radioactive iodine, particularly when micronodular and occurring in younger patients. Bone metastases often require a multimodal approach involving surgery, external beam radiotherapy, stabilization, vertebroplasty, thermal ablation, embolization, or radioiodine therapy when the lesions are iodine-avid. The priority is to prevent fractures, spinal cord compression, uncontrolled pain, and functional loss. Treatment of bone disease cannot rely exclusively on radioactive iodine when immediate mechanical risks are present.
When disease is radioactive iodine-refractory, progressive, and clinically significant, systemic therapies are considered. Antiangiogenic multikinase inhibitors, particularly lenvatinib and sorafenib, have demonstrated a benefit in progression-free survival in differentiated thyroid carcinomas refractory to radioactive iodine. In tumors with rare actionable alterations, such as neurotrophic tyrosine receptor kinase (NTRK) fusions or rearranged during transfection (RET) alterations, selective inhibitors may be used when indicated. Systemic therapy should not be initiated solely because a stable metastasis exists: there should be radiological progression, symptoms, anatomical risk, or a significant tumor burden. The decision requires assessment of progression, toxicity, comorbidities, and the clinical objective.
Prognosis depends on age, tumor size, completeness of resection, vascular invasion, extrathyroidal extension, distant metastases, iodine uptake, and histological differentiation. Minimally invasive forms with capsular invasion alone have excellent survival and a low risk of recurrence; encapsulated forms with extensive angioinvasion and widely invasive forms carry a higher risk of metastasis and disease-specific mortality. Bone metastases, non-iodine-avid disease, TERT mutations, rapid progression, or poorly differentiated transformation worsen prognosis. Follicular carcinoma should therefore not be described as uniformly favorable or uniformly aggressive: it is a disease with a risk-stratified prognosis.
Follow-up depends on the extent of surgery and the level of risk. After total thyroidectomy, serum thyroglobulin is the principal marker of persistence or recurrence, provided that it is interpreted together with anti-thyroglobulin antibodies, TSH level, analytical method, and the amount of residual thyroid tissue. After lobectomy, thyroglobulin is less specific because the remaining lobe physiologically produces thyroglobulin; in this setting, the trend over time is more important and must be considered together with ultrasound and the clinical picture. In follicular carcinoma, a progressive increase in thyroglobulin should prompt a search for pulmonary, bone, or local disease even when the neck is negative.
Cervical ultrasound remains useful for assessing the thyroid bed, the residual lobe after lobectomy, lymph nodes, and local recurrences. However, follow-up in follicular carcinoma cannot be exclusively cervical because systemic recurrence may precede or replace lymph node recurrence. In high-risk patients, those with extensive angioinvasion, elevated thyroglobulin, or known metastases, chest CT, bone imaging, targeted MRI, radioactive iodine scintigraphy, or FDG-PET must be integrated according to the disease profile. Surveillance must search for hematogenous recurrence, rather than only for nodules in the neck.
Whole-body radioactive iodine scintigraphy is useful when iodine-avid disease is suspected or after radioiodine therapy. A lesion that takes up iodine may be treated with iodine-131 if the expected benefit outweighs the risks; a lesion that does not take up iodine but continues to grow must be assessed with CT, MRI, or FDG-PET. FDG-PET becomes particularly informative when thyroglobulin is elevated and iodine scintigraphy is negative because loss of iodine avidity is often associated with increased glucose metabolism and reduced differentiation. This dissociation between thyroglobulin and scintigraphy is an important clinical signal.
Response to therapy is classified as excellent, indeterminate, biochemical incomplete, or structural incomplete. An excellent response after adequate treatment allows less intensive surveillance and less marked TSH suppression. A biochemical incomplete response requires analysis of the trend, exclusion of antibody interference, and targeted imaging. A structural incomplete response requires site-specific assessment: an unstable bone metastasis is not managed in the same way as small, stable pulmonary nodules. The structural response guides actual intervention more directly than the numerical thyroglobulin value alone.
Follow-up must be prolonged because follicular carcinoma may recur late, particularly in angioinvasive or metastatic forms. The duration and intensity of surveillance should not be identical for all patients: a completely resected, minimally invasive carcinoma may require less burdensome follow-up, whereas a carcinoma with extensive vascular invasion or metastases requires prolonged monitoring. The risk of late recurrence does not justify permanent diagnostic anxiety in low-risk cases, but it requires continuity in patients with an invasive profile.
The most characteristic oncological complication of follicular carcinoma is distant metastasis. The mechanism originates from vascular invasion: once tumor clones penetrate venous vessels, they may reach the lungs and skeleton. Pulmonary metastases may remain asymptomatic or cause cough, dyspnea, reduced respiratory function, and radiological progression. Bone metastases cause pain, pathological fractures, spinal cord compression, neurological deficits, and hypercalcemia in extensive disease. Hematogenous metastasis is therefore the complication that most clearly distinguishes follicular carcinoma from classic papillary carcinoma.
Persistent or recurrent local disease may occur in the presence of incomplete resection, positive margins, a widely invasive tumor, or extrathyroidal extension. Recurrence in the thyroid bed may involve the trachea, esophagus, muscles, recurrent laryngeal nerve, or vascular structures, making repeat surgery and local treatments more complex. A tumor invading the recurrent laryngeal nerve causes dysphonia, vocal fatigue, and a risk of aspiration; a tumor infiltrating the trachea or esophagus may cause dyspnea, hemoptysis, or dysphagia. Loss of local control is less frequent in minimally invasive forms but highly relevant in widely invasive disease.
Dedifferentiation and refractoriness to radioactive iodine represent biological complications. When the tumor reduces expression of NIS and thyroid-specific genes, iodine-131 becomes less effective or ineffective. The disease may then progress despite radioiodine therapy, requiring local treatments, external beam radiotherapy, or systemic therapies. Refractoriness is more problematic when associated with radiological progression, symptoms, bone metastases, or lesions carrying anatomical risk. The true complication is not the absence of uptake alone, but the combination of radioiodine resistance and clinically significant growth.
Surgical complications include transient or permanent hypocalcemia due to hypoparathyroidism, recurrent laryngeal nerve injury, superior laryngeal nerve injury, compressive cervical hematoma, seroma, infection, pathological scarring, and the need for thyroid hormone replacement therapy. The risk increases with extensive surgery, repeat operations, lymph node dissections, and invasive tumors. Chronic hypoparathyroidism may cause paresthesia, cramps, tetany, treatment-related nephrolithiasis, and reduced quality of life; recurrent laryngeal nerve injury may impair voice and swallowing. Surgical morbidity requires avoidance of unnecessary total thyroidectomies in minimally invasive, very-low-risk tumors.
Radioactive iodine may cause sialadenitis, xerostomia, taste alterations, nausea, cervical pain, lacrimal dysfunction, transient reduction in fertility, bone marrow toxicity at high doses, and a small increase in the risk of second malignancies in selected settings. In diffuse pulmonary metastases, repeated doses require attention to the risk of pulmonary toxicity. These effects do not contraindicate radioactive iodine when disease is high-risk or metastatic and iodine-avid, but they make indiscriminate use inappropriate. Treatment must be proportionate to the expected benefit for iodine-avid disease.
Chronic TSH suppression may cause iatrogenic subclinical thyrotoxicosis, atrial fibrillation, tachycardia, worsening angina, loss of bone mass, and an increased fracture risk, particularly in postmenopausal women and older individuals. In patients with persistent disease, the oncological benefit may justify more intense suppression; in patients who are cured and at low risk, the same degree of suppression may become harmful. The complication arises from suppression that is not recalibrated after an excellent response or reduction in risk.
Finally, there is a diagnostic complication: overtreatment of indeterminate follicular lesions. Because many follicular cytological findings do not represent carcinomas, automatically converting every indeterminate result into total thyroidectomy exposes the patient to unnecessary risks. Conversely, underestimating an angioinvasive follicular carcinoma may delay completion surgery, radioactive iodine therapy, or the search for metastases. Correct management must maintain a balance between oncological caution and limitation of iatrogenic harm, using initial surgery, definitive histology, and risk stratification as sequential steps.